Hypoactive Sexual Desire Disorder Clinical Trial
Official title:
The Effect of Individualised Homeopathic Treatment on Low Sexual Desire in Perimenopause
Low sexual desire, or decreased libido, is one of the most prevalent sexual complaints in
females. Menopause is defined as the physiologic cessation of menses brought on by a
decrease in ovarian function and is established once menses have been absent for at least
twelve months. Perimenopause refers to the period shortly before as well as the twelve
months after the last menstrual period. The duration of perimenopause varies greatly and
signs and symptoms usually begin appearing during a woman's forties. A longitudinal study
conducted in Seattle showed that women experienced a significant reduction in sexual desire
during the late perimenopausal and early postmenopausal stages, with the biggest decline in
sexual desire occurring from three years prior to two years after the final menstrual
period. Despite being a prevalent female complaint, currently no standard treatment for low
sexual desire exists. Homeopathy may offer a safe and effective solution for this common
problem, however limited research has been conducted to date.
The aim of this study is to explore the effect of individualised homeopathic treatment on
low sexual desire in perimenopausal females using detailed case studies, the desire and
arousal subscales of the Female Sexual Function Index (FSFI) as well as Item 13 of the
Female Sexual Distress Scale - Revised (FSDS-R).
Status | Completed |
Enrollment | 10 |
Est. completion date | October 2015 |
Est. primary completion date | October 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 40 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Females aged 40-60 years who are perimenopausal (up to one year after final menses) - Low sexual desire present for the last 3 months - At least 2 of the additional common signs and symptoms of perimenopause present for the last 3 months such as menorrhagia, irregular menses, amenorrhoea, hot flushes, night sweats, heart palpitations, insomnia, fatigue, mood swings, irritability, anxiety, memory and/or concentration loss, headaches, joint pain and vaginal dryness - History of normal libido, with onset of low sexual desire coinciding with or appearing after the onset of other symptoms of perimenopause. Exclusion Criteria: - Cessation of menses for more than 1 year (postmenopause) - Total hysterectomy - Early menopause (before age 40) - Pelvic or abdominal surgery in the preceding 6 months - Pregnant or lactating women or childbirth in the preceding 12 months - Gynaecological disorders such as endometriosis, uterine fibroids, dyspareunia or vaginismus - Chronic diseases that affect sexual desire - Chronic medication that can affect sexual desire such as: Hormone Replacement Therapy, oral contraceptives, anti-depressants, benzodiazepines, beta-blockers, opioids, carbamazepine or antihistamines. |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
South Africa | University of Johannesburg | Johannesburg | Gauteng |
Lead Sponsor | Collaborator |
---|---|
University of Johannesburg |
South Africa,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Female Sexual Function Index | The Female Sexual Function Index (FSFI) covers six domains of female sexual function namely: desire, subjective arousal, lubrication, orgasm, satisfaction and pain. The study has shown a high test-retest reliability and a high degree of internal consistency for each of the six domains. | Every fourth week for twelve weeks. | No |
Secondary | The Female Sexual Distress Scale (FSDS-R) | The FSDS-R can be used to identify distress related to sexual function, as well as to support a potential diagnosis of sexual dysfunction. It has demonstrated the discriminant validity and test-retest reliability of both the FSDS-R and FSDS-R Item 13 alone in women suffering from Hypoactive Sexual Desire Disorder. Item 13 of the scale specifically pertains to low sexual desire and has been demonstrated to have good content validity, thereby making it sufficient as a stand-alone measure for low sexual desire. | Every fourth week for twelve weeks. | No |
Secondary | Individual participant case histories | Individual case histories of each participant will be recorded during each consultation, by means of the researcher's case notes, in order to collect qualitative data. | Every fourth week for twelve weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02430987 -
Low Sexual Desire and Metabolic Syndrome
|
N/A | |
Completed |
NCT01432665 -
Lybrido for Female Sexual Dysfunction
|
Phase 2 | |
Terminated |
NCT00551785 -
Surveillance Study of Women Taking Intrinsa®
|
Phase 4 | |
Completed |
NCT03232801 -
A Mindfulness-based Intervention for Older Women With Low Sexual Desire
|
N/A | |
Recruiting |
NCT04179734 -
Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
|
Phase 4 | |
Terminated |
NCT02770768 -
Effects of Flibanserin on the Pre- and Post-menopausal Female Brain
|
N/A | |
Completed |
NCT01235754 -
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
|
Phase 3 | |
Completed |
NCT03287232 -
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
|
Phase 3 | |
Completed |
NCT00384046 -
Testosterone Therapy in Naturally Menopausal Women With Low Sexual Desire Receiving Transdermal Estrogen
|
Phase 3 | |
Completed |
NCT00331123 -
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
|
Phase 3 | |
Recruiting |
NCT04943068 -
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
|
Phase 3 | |
Completed |
NCT03463707 -
BP101 for Adults With Female Sexual Dysfunction
|
Phase 3 | |
Completed |
NCT01208038 -
Testosterone Patch's Effects on the Cardiovascular System and Libido
|
Phase 4 | |
Completed |
NCT00657501 -
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
|
Phase 3 | |
Completed |
NCT04336891 -
Effect of Testosterone Treatment on Clitoral Arteries' Hemodynamic Parameters.
|
||
Completed |
NCT01382719 -
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
|
Phase 2 | |
Recruiting |
NCT00916396 -
Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder
|
N/A | |
Completed |
NCT00331214 -
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
|
Phase 3 | |
Completed |
NCT00034021 -
Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction
|
Phase 2 | |
Completed |
NCT00338312 -
Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
|
Phase 3 |